Predict Intracellular Drug Binding from Phospholipid Affinity Estimate intracellular unbound drug fractions (fu,cell) in minutes using a rapid cell- free assay. Plasma protein binding does not predict intracellular drug binding, because intracellular drug distribution is largely driven by interactions with cellular membranes. The TRANSIL Intracellular Binding Kit enables rapid determination of drug affinity to phospholipid membranes — the dominant sink for intracellular drug binding. Key benefits Predict intracellular drug binding Estimate intracellular unbound fraction (fu,cell) Cell-free alternative to complex cell assays Results in less than 30 minutes Why Intracellular Drug Binding Matters For many drugs, pharmacological targets are located inside cells rather than in plasma. Consequently, the pharmacologically relevant concentration is the unbound drug concentration inside the cell. However, drugs can bind extensively to intracellular structures such as membranes, lipids, and proteins. This nonspecific binding reduces the fraction of drug that remains freely available to interact with intracellular targets. As a result, the intracellular unbound fraction (fu,cell) and the resulting intracellular bioavailability (Fic) have become important parameters in modern drug discovery. Intracellular unbound drug concentrations determine target engagement for many therapeutic targets, including kinases, nuclear receptors, and intracellular enzymes. Consequently, intracellular binding can strongly influence pharmacodynamics, tissue distribution, and intracellular drug exposure. Despite its importance, measuring intracellular binding using cell-based methods is labor-intensive, low-throughput, and difficult to implement in early discovery programs. Moreover, plasma protein binding does not reliably predict intracellular drug binding, making dedicated methods necessary to estimate intracellular drug exposure. Phospholipid Binding Drives Intracellular Drug Binding Studies comparing drug binding across multiple cell types show that cellular phospholipid content strongly correlates with intracellular drug binding. Experiments further demonstrate that drug binding measured using phospholipid membranes correlates well with intracellular binding measured in cells. These findings show that phospholipid membranes constitute the dominant sink for nonspecific intracellular drug binding, making phospholipid-based assays a powerful tool to estimate intracellular binding behavior. A Cell-Free Assay to Estimate Intracellular Drug Binding The TRANSIL Intracellular Binding Kit provides a rapid cell-free approach to quantify drug affinity for phospholipid membranes, which are the dominant contributors to nonspecific intracellular drug binding. The assay measures the distribution of a compound between buffer and phospholipid membranes immobilized on porous silica beads. Because cellular drug binding is largely driven by interactions with phospholipid membranes, these measurements can be used to estimate: intracellular membrane binding intracellular fraction unbound (fu,cell) intracellular drug exposure This provides a scalable alternative to complex cell-based methods for early drug discovery. Quantifying Membrane Affinity in a Simple Equilibrium Assay The TRANSIL Intracellular Binding assay determines drug affinity to phospholipid membranes by measuring the distribution of a compound between buffer and lipid membranes. In the TRANSIL assay, compounds are incubated with increasing amounts of phospholipid membrane immobilized on porous silica beads until equilibrium is reached between the aqueous buffer phase and the membrane phase. At equilibrium, the concentration of free compound remaining in the buffer () is measured. The total amount of compound in the system () is then related to the buffer concentration and the amount of lipid present. Plotting the ratio against the lipid amount yields a linear relationship. The slope of this line reflects the extent to which the compound partitions into the membrane phase and therefore provides a direct measure of membrane affinity. Because membrane affinity is determined from the slope of the versus lipid amount relationship, the estimate is largely insensitive to non-specific binding that does not scale with lipid amount. Such binding shifts the intercept but does not affect the slope. As a result, the TRANSIL Intracellular Binding Kit provides reliable membrane affinity estimates even when non-specific binding is elevated. Workflow 1. Add test compound to wells containing membrane coated beads 2. Incubate for 12 minutes to reach equilibrium 3. Separate beads by centrifugation 4. Quantify the compound concentration in the supernatant 5. Determine membrane affinity from the slope of the versus lipid amount plot By analyzing the concentration remaining in solution across wells containing different membrane surface areas, the membrane affinity of the compound is calculated. The assay uses six membrane concentrations, or surface areas, plus reference wells to determine membrane affinity with internal consistency controls. Any analytical method can be used for quantification, including LC-MS/MS, HPLC- UV, or scintillation counting. Applications The TRANSIL Intracellular Binding Kit supports multiple applications in pharmacokinetics and drug discovery: Lead optimization Identify compounds with excessive intracellular binding that may reduce intracellular target engagement. PK/PD modeling Provide experimentally derived intracellular unbound fractions for mechanistic pharmacokinetic models. Intracellular drug exposure Estimate intracellular fraction unbound (fu,cell) to understand drug availability at intracellular targets. Prediction of intracellular bioavailability Combine fu,cell with cellular uptake measurements to estimate intracellular bioavailability (Fic). Understanding intracellular drug disposition Investigate how drug binding to phospholipids influences intracellular drug distribution. Comparing compound series Identify compounds with excessive intracellular binding during lead optimization. Mechanistic ADME modelling Provide experimental input for mechanistic pharmacokinetic models. Validation Drug affinity to phospholipid membranes measured with the TRANSIL assay correlates with experimentally determined intracellular unbound fractions measured in cellular systems (Figure 1). Predicted intracellular unbound fractions derived from phospholipid membrane affinity measurements show good agreement with experimentally measured values across both wild-type (WT) cells and phospholipid- enriched (PL⁺) cells. This demonstrates that phospholipid membrane affinity is a major determinant of intracellular drug binding and can be used to estimate intracellular unbound drug fractions using a rapid cell-free assay. Measurements of intracellular unbound fractions across multiple cell types show that absolute values can vary substantially between cell types (Figure 2). However, the relative ranking of compounds remains largely consistent. These differences reflect variations in cellular phospholipid content, which represents the dominant binding sink for many drugs inside cells. Together, these results demonstrate that intracellular drug binding is largely determined by phospholipid membranes and can therefore be predicted from phospholipid membrane affinity measurements. Figure 1: Prediction of intracellular drug binding. Predicted intracellular unbound fractions derived from phospholipid membrane affinity measurements correlate with experimentally determined intracellular unbound fractions measured in wild-type (WT) and phospholipid-enriched (PL⁺) cells. The dashed line indicates perfect agreement between prediction and experiment. Figure 2: Intracellular drug binding across different cell types. The intracellular unbound fraction for a panel of drugs was measured in six different cell types. While the relative ranking of compounds is largely preserved, the absolute values vary substantially between cell types, reflecting differences in cellular phospholipid content.
